Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEROY B VAUGHAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1366646697
CMS profile
629902
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$35,628.74

47 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEROY B VAUGHAN

NPI 1366646697 · CMS profile ID 629902

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

47 matching records · $35,628.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 47 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–47 of 47.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $7.4212/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274700 CMS
Lilly USA, LLC $13.5812/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135152798 CMS
GENZYME CORPORATION $18.2311/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139755631 CMS
Cumberland Pharmaceuticals, Inc. $16.7610/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146404142 CMS
ABBVIE INC. $17.7010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274698 CMS
ABBVIE INC. $4,025.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274694 CMS
ABBVIE INC. $2,875.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274696 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560718 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560720 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560722 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560724 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560726 CMS
ABBVIE INC. $124.7409/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274692 CMS
ABBVIE INC. $34.8209/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274688 CMS
ABBVIE INC. $68.3409/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274690 CMS
La Jolla Pharmaceutical Company $25.3307/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154251648 CMS
ABBVIE INC. $4,025.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274686 CMS
ABBVIE INC. $26.1506/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274682 CMS
ABBVIE INC. $2.0406/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274684 CMS
ABBVIE INC. $4,025.0006/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274680 CMS
ABBVIE INC. $122.5306/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274676 CMS
ABBVIE INC. $111.2206/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274678 CMS
ABBVIE INC. $2,875.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274674 CMS
ABBVIE INC. $28.1005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274668 CMS
ABBVIE INC. $71.5005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274670 CMS
ABBVIE INC. $330.9805/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274672 CMS
ABBVIE INC. $2,875.0005/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274666 CMS
ABBVIE INC. $120.4605/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274664 CMS
Melinta Therapeutics, LLC $21.9105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140483472 CMS
ABBVIE INC. $112.7504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274662 CMS
Melinta Therapeutics, LLC $25.6604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140485115 CMS
ABBVIE INC. $2,875.0004/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274660 CMS
Paratek Pharmaceuticals, Inc. $15.0404/11/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113922556 CMS
ABBVIE INC. $4,025.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274658 CMS
ABBVIE INC. $99.3903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274656 CMS
Ferring Pharmaceuticals Inc. $32.3603/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137516606 CMS
ABBVIE INC. $4.0403/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274654 CMS
ABBVIE INC. $2.5903/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274646 CMS
ABBVIE INC. $125.9003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274648 CMS
ABBVIE INC. $199.6603/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274650 CMS
ABBVIE INC. $25.0003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274652 CMS
ABBVIE INC. $3.1903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274644 CMS
Grifols USA, LLC $26.7502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124755306 CMS
ABBVIE INC. $2,875.0002/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274642 CMS
ABBVIE INC. $2,875.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274638 CMS
ABBVIE INC. $18.1002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274640 CMS
ABBVIE INC. $120.5001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274636 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $59.09 3
PY2022 $20.46 1
PY2023 $6,049.96 8
PY2024 $35,628.74 47
PY2025 $13,193.85 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,807,448.32 336
PY2024 Principal investigator $6,183,192.34 199
PY2023 Recipient $1,340.62 4
PY2023 Principal investigator $9,068,826.97 4,189
PY2022 Principal investigator $2,728,925.31 3,261

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

3,261 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $41,881.50 12/21/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949773537
Principal investigator 1 PFIZER INC. $63,194.96 12/17/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949773711
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579767
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579769
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579771
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579773
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579775
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579777
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579779
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579781
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579783
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579785
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579787
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579789
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579791
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579793
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579795
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579797
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579799
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579801
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579803
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579805
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579807
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579809
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579811
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579813
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579815
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579817
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579819
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579821
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579823
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579825
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579827
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579829
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579831
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579833
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579835
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579837
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579839
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579841
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579843
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579845
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579847
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579849
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579851
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579853
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579855
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579857
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579859
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579861
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579863
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579865
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579867
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579869
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579871
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579873
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579875
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579877
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579879
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579881
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579883
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579885
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579887
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579889
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579891
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579893
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579895
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579897
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579899
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579901
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579903
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579905
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579907
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579909
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579911
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579913
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579915
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579917
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579919
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579921
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579923
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579925
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579927
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579929
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579931
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579933
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579935
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579937
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579939
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579941
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579943
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579945
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579947
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579949
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579951
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579953
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579955
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579957
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579959
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579961
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579963
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579965
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579967
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579969
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579971
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579973
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579975
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579977
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579979
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579981
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579983
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579985
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579987
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579989
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579991
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579993
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579995
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579997
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579999
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580001
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580003
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580005
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580007
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580009
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580011
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580013
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580015
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580017
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580019
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580021
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580023
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580025
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580027
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580029
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580031
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580033
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580035
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580037
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580039
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580041
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580043
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580045
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580047
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580049
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580051
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580053
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580055
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580057
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580059
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580061
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580063
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580065
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580067
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580069
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580071
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580073
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580075
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580077
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580079
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580081
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580083
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580085
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580087
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580089
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580093
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580095
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580097
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580099
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580101
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580103
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580105
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580107
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580109
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580111
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580113
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580115
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580117
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580119
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580121
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580123
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580125
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580127
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580129
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580131
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580133
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580135
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580137
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580139
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580141
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580143
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580145
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580147
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580149
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580151
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580153
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580155
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580157
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580159
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580161
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580163
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580165
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580167
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580169
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580171
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580173
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580175
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580177
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580179
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580181
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580183
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580185
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580187
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580189
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580191
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580193
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580195
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580197
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580199
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580201
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580203
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580205
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580207
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580209
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580211
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580213
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580215
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580217
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580219
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580221
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580223
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580225
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580227
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580229
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580231
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580233
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580235
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580237
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580239
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580241
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580243
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580245
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580247
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580249
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580251
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580253
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580255
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580257
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580259
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580261
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580263
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580265
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580267
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580269
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580271
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580273
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580275
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580277
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580279
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580281
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580283
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580285
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580287
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580289
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580291
Principal investigator 1 ModernaTX, Inc. $1,078.33 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580293
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580295
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580297
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580299
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580301
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580303
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580305
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580307
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580309
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580311
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580315
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580317
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580319
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580321
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580323
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580325
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580327
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580329
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580331
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580333
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580335
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580337
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580339
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580341
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580343
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580345
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580347
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580349
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580351
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580353
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580355
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580357
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580359
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580361
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580363
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580365
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580369
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580371
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580373
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580375
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580377
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580379
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580381
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580383
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580385
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580387
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580389
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580391
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580393
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580395
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580397
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580399
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580401
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580403
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580405
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580407
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580409
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580411
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580413
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580415
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580417
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580419
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580421
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580423
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580425
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580427
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580429
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580431
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580433
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580435
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580437
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580439
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580441
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580443
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580445
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580447
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580449
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580451
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580453
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580455
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580457
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580459
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580461
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580463
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580465
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580467
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580469
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580471
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580473
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580475
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580477
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580479
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580481
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580483
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580485
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580487
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580489
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580491
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580493
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580495
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580497
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580499
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580501
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580503
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580505
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580507
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580509
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580511
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580513
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580515
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580517
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580519
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580521
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580523
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580525
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580527
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580529
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580531
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580533
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580535
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580537
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580539
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580541
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580543
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580545
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580547
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580549
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580551
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580553
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580555
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580557
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580559
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580561
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580563
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580565
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580567
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580569
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580571
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580573
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580575
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580577
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580579
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580581
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580583
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580585
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580587
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580589
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580591
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580593
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580595
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580597
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580599
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580601
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580603
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580605
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580607
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580609
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580611
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580613
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580615
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580617
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580619
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580621
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580623
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580625
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580627
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580629
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580631
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580633
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580635
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580637
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580639
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580641
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580643
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580645
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580647
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580649
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580651
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580653
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580655
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580657
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580659
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580661
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580663
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580665
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580667
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580669
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580671
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580673
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580675
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580677
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580679
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580681
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580683
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580685
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580687
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580689
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580691
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580693
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580695
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580697
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580699
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580701
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580703
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580705
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580707
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580709
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580711
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580713
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580715
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580717
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580719
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580721
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580723
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580725
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580727
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580729
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580731
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580733
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580735
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580737
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580739
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580741
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580743
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580745
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580747
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580749
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580751
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580753
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580755
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580757
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580759
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580761
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580763
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580765
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580767
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580769
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580771
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580773
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580775
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580777
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580779
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580781
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580783
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580785
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580787
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580789
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580791
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580793
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580795
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580797
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580799
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580801
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580803
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580805
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580807
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580809
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580811
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580813
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580815
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580817
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580819
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580821
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580823
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580825
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580827
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580829
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580831
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580833
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580835
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580837
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580839
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580841
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580843
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580845
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580847
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580849
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580851
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580853
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580855
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580857
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580859
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580861
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580863
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580865
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580867
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580869
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580871
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580873
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580875
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580877
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580879
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580881
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580883
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580885
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580887
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580889
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580891
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580893
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580895
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580897
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580899
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580901
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580903
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580905
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580907
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580909
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580911
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580913
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580915
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580917
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580919
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580921
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580923
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580925
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580927
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580929
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580931
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580933
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580935
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580937
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580939
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580941
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580943
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580945
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580947
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580949
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580951
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580953
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580955
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580957
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580959
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580961
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580963
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580965
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580967
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580969
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580971
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580973
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580975
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580977
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580979
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580981
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580983
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580985
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580987
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580989
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580991
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580993
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580995
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580997
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963580999
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581001
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581003
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581005
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581007
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581009
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581011
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581013
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581015
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581017
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581019
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581021
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581023
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581025
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581027
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581029
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581031
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581033
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581035
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581037
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581039
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581041
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581043
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581045
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581047
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581049
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581051
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581053
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581055
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581057
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581059
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581061
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581063
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581065
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581067
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581069
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581071
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581073
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581075
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581077
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581079
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581081
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581083
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581085
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581087
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581089
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581091
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581093
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581095
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581097
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581099
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581101
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581103
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581105
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581107
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581109
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581111
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581113
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581115
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581117
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581119
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581121
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581123
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581125
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581127
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581129
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581131
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581133
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581135
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581137
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581139
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581141
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581143
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581145
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581147
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581149
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581151
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581153
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581155
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581157
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581159
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581161
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581163
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581165
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581167
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581169
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581171
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581173
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581175
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581177
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581179
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581181
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581183
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581185
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581187
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581189
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581191
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581193
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581195
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581197
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581199
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581201
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581203
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581205
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581207
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581209
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581211
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581213
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581215
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581217
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581219
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581221
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581223
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581225
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581227
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581229
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581231
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581233
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581235
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581237
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581239
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581241
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581243
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581245
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581247
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581249
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581251
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581253
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581255
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581257
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581259
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581261
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581263
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581265
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581267
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581269
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581271
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581273
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581275
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581277
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581279
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581281
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581283
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581285
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581287
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581289
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581291
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581293
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581295
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581297
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581299
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581301
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581303
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581305
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581307
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581309
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581311
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581313
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581315
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581317
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581319
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581321
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581323
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581325
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581327
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581329
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581331
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581333
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581335
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581337
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581339
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581341
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581343
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581345
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581347
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581349
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581351
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581353
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581355
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581357
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581359
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581361
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581363
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581365
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581367
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581369
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581371
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581373
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581375
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581377
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581379
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581381
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581383
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581385
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581387
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581389
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581391
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581393
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581395
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581397
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581399
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581401
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581403
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581405
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581407
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581409
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581411
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581413
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581415
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581417
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581419
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581421
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581423
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581425
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581427
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581429
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581431
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581433
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581435
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581437
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581439
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581441
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581443
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581445
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581447
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581449
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581451
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581453
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581455
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581457
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581459
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581461
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581463
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581465
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581467
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581469
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581471
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581473
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581475
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581477
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581479
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581481
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581483
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581485
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581487
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581489
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581491
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581493
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581495
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581497
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581499
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581501
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581503
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581505
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581507
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581509
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581511
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581513
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581515
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581517
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581519
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581521
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581523
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581525
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581527
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581529
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581531
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581533
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581535
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581537
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581539
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581541
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581543
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581545
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581547
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581549
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581551
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581553
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581555
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581557
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581559
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581561
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581563
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581565
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581567
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581569
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581571
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581573
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581575
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581577
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581579
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581581
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581583
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581585
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581587
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581589
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581591
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581593
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581595
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581597
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581599
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581601
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581603
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581605
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581607
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581609
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581611
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581613
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581615
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581617
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581619
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581621
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581623
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581625
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581627
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581629
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581631
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581633
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581635
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581637
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581639
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581641
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581643
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581645
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581647
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581649
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581651
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581653
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581655
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581657
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581659
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581661
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581663
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581665
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581667
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581669
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581671
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581673
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581675
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581677
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581679
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581681
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581683
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581685
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581687
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581689
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581691
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581693
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581695
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581697
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581699
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581701
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581703
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581705
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581707
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581709
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581711
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581713
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581715
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581717
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581719
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581721
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581723
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581725
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581727
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581729
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581731
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581733
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581735
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581737
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581739
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581741
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581743
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581745
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581747
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581749
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581751
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581753
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581755
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581757
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581759
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581761
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581763
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581765
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581767
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581769
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581771
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581773
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581775
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581777
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581779
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581781
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581783
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581785
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581787
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581789
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581791
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581793
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581795
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581797
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581799
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581801
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581803
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581805
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581807
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581809
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581811
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581813
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581815
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581817
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581819
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581821
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581823
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581825
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581827
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581829
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581831
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581833
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581835
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581837
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581839
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581841
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581843
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581845
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581847
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581849
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581851
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581853
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581855
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581857
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581859
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581861
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581863
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581865
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581867
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581869
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581871
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581873
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581875
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581877
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581879
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581881
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581883
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581885
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581887
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581889
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581891
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581893
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581895
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581897
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581899
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581901
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581903
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581905
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581907
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581909
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581911
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581913
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581915
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581917
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581919
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581921
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581923
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581925
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581927
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581929
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581931
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581933
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581935
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581937
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581939
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581941
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581943
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581945
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581947
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581949
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581951
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581953
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581955
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581957
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581959
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581961
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581963
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581965
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581967
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581969
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581971
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581973
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581975
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581977
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581979
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581981
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581983
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581985
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581987
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581989
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581991
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581993
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581995
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581997
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963581999
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582001
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582003
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582005
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582007
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582009
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582011
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582013
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582015
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582017
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582019
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582021
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582023
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582025
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582027
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582029
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582031
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582033
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582035
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582037
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582039
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582041
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582043
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582045
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582047
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582049
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582051
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582053
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582055
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582057
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582059
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582061
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582063
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582065
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582067
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582069
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582071
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582073
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582075
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582077
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582079
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582081
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582083
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582085
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582087
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582089
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582091
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582093
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582095
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582097
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582099
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582101
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582103
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582105
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582107
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582109
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582111
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582113
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582115
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582117
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582119
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582121
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582123
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582125
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582127
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582129
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582131
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582133
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582135
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582137
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582139
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582141
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582143
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582145
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582147
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582149
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582151
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582153
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582155
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582157
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582159
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582161
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582163
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582165
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582167
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582169
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582171
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582173
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582175
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582177
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582179
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582181
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582183
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582185
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582187
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582189
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582191
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582193
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582195
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582197
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582199
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582201
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582203
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582205
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582207
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582209
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582211
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582213
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582215
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582217
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582219
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582221
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582223
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582225
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582227
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582229
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582231
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582233
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582235
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582237
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582239
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582241
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582243
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582245
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582247
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582249
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582251
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582253
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582255
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582257
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582259
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582261
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582263
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582265
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582267
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582269
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582271
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582273
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582275
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582277
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582279
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582281
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582283
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582285
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582287
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582289
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582291
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582293
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582295
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582297
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582299
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582301
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582303
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582305
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582307
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582309
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582311
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582313
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582315
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582317
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582319
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582321
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582323
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582325
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582327
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582329
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582331
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582333
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582335
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582337
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582339
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582341
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582343
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582345
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582347
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582349
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582351
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582353
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582355
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582357
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582359
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582361
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582363
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582365
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582367
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582369
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582371
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582373
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582375
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582377
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582379
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582381
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582383
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582385
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582387
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582389
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582391
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582393
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582395
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582397
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582399
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582401
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582403
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582405
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582407
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582409
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582411
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582413
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582415
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582417
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582419
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582421
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582423
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582425
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582427
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582429
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582431
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582433
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582435
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582437
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582439
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582441
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582443
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582445
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582447
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582449
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582451
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582453
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582455
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582457
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582459
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582461
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582463
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582465
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582467
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582469
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582471
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582473
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582475
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582477
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582479
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582481
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582483
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582485
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582487
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582489
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582491
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582493
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582495
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582497
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582499
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582501
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582503
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582505
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582507
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582509
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582511
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582513
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582515
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582517
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582519
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582521
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582523
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582525
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582527
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582529
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582531
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582533
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582535
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582537
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582539
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582541
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582543
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582545
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582547
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582549
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582551
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582553
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582555
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582557
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582559
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582561
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582563
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582565
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582567
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582569
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582571
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582573
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582579
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582581
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582583
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582585
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582587
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582589
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582591
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582593
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582595
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582597
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582599
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582601
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582603
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582605
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582607
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582609
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582611
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582613
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582615
Principal investigator 1 ModernaTX, Inc. $2,547.48 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582617
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582619
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582621
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582623
Principal investigator 1 ModernaTX, Inc. $13.80 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582625
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582627
Principal investigator 1 ModernaTX, Inc. $1,956.84 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582629
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582631
Principal investigator 1 ModernaTX, Inc. $3,655.62 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582633
Principal investigator 1 ModernaTX, Inc. $666.54 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582635
Principal investigator 1 ModernaTX, Inc. $812.82 12/16/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963582637
Principal investigator 1 PFIZER INC. $97,979.31 12/16/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949773539
Principal investigator 1 PFIZER INC. $564,515.45 12/10/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949774975
Principal investigator 1 PFIZER INC. $57,782.67 12/03/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949773713
Principal investigator 1 PFIZER INC. $77,880.99 11/23/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780309
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575957
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575959
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575961
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575963
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575975
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575977
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575979
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575981
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575983
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575985
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575987
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575989
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575991
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575993
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575995
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575997
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575999
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576001
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576003
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576005
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576007
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576157
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576159
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576161
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576163
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576165
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576167
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576169
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576171
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576173
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576175
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576177
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576179
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576181
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576183
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576185
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576187
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576203
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576205
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576207
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576209
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576211
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576213
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576215
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576217
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576219
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576221
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576223
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576225
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576227
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576229
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576231
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576233
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576235
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576237
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576239
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576241
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576243
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576245
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576247
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576249
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576251
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576253
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576255
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576257
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576259
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576261
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576263
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576265
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576267
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576269
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576271
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576273
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576275
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576277
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576279
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576281
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576283
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576285
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576291
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576293
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576295
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576297
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576299
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576301
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576303
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576305
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576307
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576313
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576315
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576317
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576319
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576321
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576323
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576325
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576327
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576329
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576331
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576333
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576335
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576337
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576341
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576343
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576345
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576347
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576349
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576351
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576353
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576355
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576357
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576359
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576361
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576363
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576365
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576367
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576369
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576371
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576373
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576375
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576377
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576379
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576381
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576383
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576385
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576387
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576391
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576393
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576395
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576397
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576399
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576401
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576403
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576405
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576407
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576409
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576411
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576413
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576415
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576417
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576419
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576421
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576423
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576425
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576427
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576429
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576437
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576439
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576441
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576443
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576445
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576447
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576449
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576451
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576453
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576455
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576457
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576459
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576461
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576463
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576465
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576467
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576473
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576475
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576477
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576479
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576481
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576483
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576485
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576487
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576489
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576491
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576493
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576495
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576497
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576499
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576501
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576503
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576505
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576507
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576509
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576511
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576513
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576515
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576517
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576519
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576521
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576531
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576533
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576535
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576537
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576539
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576541
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576543
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576545
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576547
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576549
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576551
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576553
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576555
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576557
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576559
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576561
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576563
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576565
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576567
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576569
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576571
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576573
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576575
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576577
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576579
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576581
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576583
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576585
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576593
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576595
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576597
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576599
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576601
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576603
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576605
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576607
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576609
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576611
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576613
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576615
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576617
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576619
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576629
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576631
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576633
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576635
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576637
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576639
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576641
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576643
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576645
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576647
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576649
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576651
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576653
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576655
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576657
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576659
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576661
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576663
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576665
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576667
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576669
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576671
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576673
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576675
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576677
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576679
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576681
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576683
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576685
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576691
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576693
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576695
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576697
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576699
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576701
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576703
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576705
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576707
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576709
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576711
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576713
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576715
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576717
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576719
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576721
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576723
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576725
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576727
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576729
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576731
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576733
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576735
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576737
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576739
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576741
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576743
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576745
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576747
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576749
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576751
Principal investigator 1 ModernaTX, Inc. $1,078.33 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576753
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576755
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576757
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576759
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576761
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576763
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576765
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576771
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576773
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576775
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576777
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576779
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576781
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576783
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576785
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576789
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576791
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576793
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576795
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576797
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576799
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576801
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576803
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576805
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576807
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576809
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576811
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576813
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576815
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576817
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576819
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576821
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576827
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576829
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576831
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576833
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576835
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576837
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576839
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576841
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576843
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576845
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576847
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576849
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576851
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576853
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576855
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576857
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576859
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576861
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576863
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576865
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576867
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576869
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576871
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576873
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576877
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576879
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576881
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576883
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576885
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576887
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576889
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576891
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576893
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576895
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576897
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576899
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576901
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576903
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576905
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576907
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576909
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576911
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576913
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576915
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576919
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576921
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576923
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576925
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576927
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576929
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576931
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576933
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576935
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576937
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576939
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576941
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576943
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576945
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576947
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576949
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576951
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576953
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576955
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576957
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576959
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576961
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576963
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576965
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576967
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576969
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576971
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576973
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576975
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576977
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576979
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576981
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576987
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576989
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576991
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576993
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576995
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576997
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576999
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577001
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577003
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577005
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577007
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577009
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577011
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577013
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577015
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577017
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577019
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577021
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577023
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577037
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577039
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577041
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577043
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577045
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577047
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577049
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577051
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577053
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577055
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577057
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577065
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577067
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577069
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577071
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577073
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577075
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577077
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577079
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577081
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577083
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577085
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577087
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577089
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577091
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577093
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577095
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577097
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577099
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577101
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577103
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577105
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577117
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577119
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577121
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577123
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577125
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577127
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577129
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577139
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577141
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577143
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577145
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577147
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577149
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577151
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577153
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577155
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577157
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577159
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577161
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577163
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577165
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577167
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577169
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577177
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577179
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577181
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577183
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577185
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577187
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577189
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577191
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577193
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577195
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577197
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577199
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577201
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577203
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577205
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577207
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577209
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577211
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577213
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577215
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577217
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577219
Principal investigator 1 ModernaTX, Inc. $1,078.33 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577221
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577223
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577225
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577227
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577229
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577231
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577233
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577235
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577237
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577239
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577241
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577243
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577245
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577247
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577249
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577251
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577253
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577255
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577257
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577259
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577261
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577263
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577265
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577273
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577275
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577277
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577279
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577281
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577283
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577285
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577287
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577289
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577291
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577293
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577295
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577297
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577299
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577301
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577303
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577305
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577307
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577309
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577311
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577313
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577315
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577317
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577319
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577321
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577323
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577325
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577327
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577329
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577331
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577333
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577335
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577337
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577339
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577341
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577349
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577351
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577353
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577355
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577357
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577359
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577363
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577365
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577367
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577369
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577371
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577373
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577375
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577377
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577379
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577389
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577391
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577393
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577395
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577397
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577399
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577401
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577403
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577405
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577407
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577409
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577411
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577413
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577415
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577417
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577419
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577421
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577423
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577425
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577427
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577429
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577431
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577433
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577435
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577443
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577445
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577447
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577449
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577451
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577453
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577455
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577457
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577459
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577461
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577465
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577467
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577469
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577471
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577473
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577475
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577477
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577479
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577481
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577483
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577485
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577487
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577489
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577491
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577493
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577495
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577497
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577499
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577501
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577503
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577505
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577507
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577509
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577511
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577513
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577515
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577517
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577519
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577521
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577523
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577525
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577527
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577529
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577531
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577533
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577535
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577537
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577539
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577541
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577543
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577545
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577553
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577555
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577557
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577559
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577561
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577563
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577565
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577567
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577569
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577571
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577573
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577575
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577577
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577579
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577581
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577583
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577585
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577587
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577589
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577591
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577593
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577595
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577597
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577611
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577613
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577615
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577617
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577619
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577621
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577623
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577625
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577627
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577629
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577631
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577633
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577635
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577637
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577639
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577641
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577643
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577645
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577647
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577649
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577651
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577653
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577655
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577657
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577659
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577661
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577663
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577665
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577667
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577669
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577671
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577673
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577675
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577677
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577679
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577681
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577683
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577687
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577689
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577691
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577693
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577695
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577697
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577699
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577701
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577703
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577705
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577707
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577709
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577711
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577713
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577715
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577717
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577719
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577721
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577723
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577725
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577727
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577729
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577731
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577733
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577735
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577737
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577739
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577741
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577743
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577745
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577747
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577749
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577751
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577753
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577755
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577761
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577763
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577765
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577767
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577769
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577771
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577773
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577775
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577777
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577779
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577781
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577783
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577785
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577787
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577789
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577791
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577793
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577795
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577797
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577799
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577801
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577803
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577805
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577807
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577809
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577811
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577813
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577815
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577817
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577819
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577821
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577823
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577825
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577827
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577829
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577831
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577833
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577835
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577837
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577839
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577853
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577855
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577857
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577859
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577861
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577863
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577865
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577867
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577869
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577871
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577873
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577875
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577877
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577879
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577881
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577889
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577891
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577893
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577895
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577897
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577899
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577901
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577903
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577905
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577907
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577909
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577911
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577913
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577915
Principal investigator 1 ModernaTX, Inc. $1,078.33 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577917
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577919
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577921
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577923
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577925
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577927
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577929
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577931
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577941
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577943
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577945
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577947
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577949
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577951
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577953
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577955
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577957
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577959
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577961
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577963
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577965
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577967
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577969
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577971
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577973
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577975
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577977
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577979
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577981
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577983
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577985
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577987
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577993
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577995
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577997
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577999
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578001
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578003
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578005
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578007
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578009
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578011
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578013
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578015
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578017
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578019
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578021
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578023
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578025
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578027
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578029
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578031
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578033
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578035
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578037
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578039
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578041
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578043
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578045
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578047
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578049
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578051
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578059
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578061
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578063
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578065
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578067
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578069
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578071
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578073
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578075
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578077
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578079
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578081
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578083
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578085
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578087
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578089
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578091
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578093
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578095
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578097
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578099
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578101
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578103
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578105
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578107
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578111
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578113
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578115
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578117
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578119
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578121
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578127
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578129
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578131
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578133
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578135
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578137
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578139
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578141
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578143
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578145
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578147
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578149
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578151
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578153
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578155
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578157
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578159
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578161
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578163
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578165
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578167
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578169
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578171
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578173
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578175
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578177
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578179
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578181
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578183
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578185
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578187
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578189
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578191
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578193
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578195
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578197
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578199
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578201
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578203
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578217
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578219
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578221
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578223
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578225
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578227
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578229
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578231
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578233
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578235
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578237
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578243
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578245
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578247
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578249
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578251
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578253
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578255
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578257
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578259
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578261
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578263
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578265
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578267
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578269
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578271
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578273
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578275
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578277
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578279
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578281
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578283
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578285
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578287
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578289
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578291
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578293
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578295
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578297
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578299
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578301
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578303
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578305
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578307
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578309
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578311
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578313
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578317
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578319
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578321
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578323
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578325
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578327
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578329
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578331
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578333
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578335
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578337
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578339
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578341
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578343
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578345
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578347
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578349
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578351
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578353
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578355
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578357
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578359
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578361
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578363
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578365
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578367
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578369
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578371
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578373
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578377
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578379
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578381
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578383
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578385
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578387
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578389
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578391
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578393
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578395
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578397
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578399
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578401
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578403
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578405
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578407
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578409
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578411
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578413
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578415
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578417
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578419
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578421
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578423
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578425
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578427
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578429
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578431
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578433
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578435
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578437
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578447
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578449
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578451
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578453
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578455
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578457
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578459
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578461
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578463
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578465
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578467
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578469
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578471
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578473
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578475
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578477
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578479
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578481
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578483
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578485
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578487
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578489
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578491
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578493
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578495
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578497
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578499
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578501
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578511
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578513
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578515
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578517
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578519
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578521
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578523
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578525
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578527
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578529
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578531
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578533
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578535
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578537
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578539
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578541
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578543
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578545
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578547
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578549
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578551
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578553
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578555
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578557
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578559
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578561
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578563
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578565
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578567
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578569
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578571
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578573
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578575
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578577
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578579
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578581
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578583
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578591
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578593
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578595
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578597
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578599
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578601
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578603
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578605
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578607
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578609
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578611
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578613
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578615
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578617
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578619
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578621
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578623
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578625
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578627
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578629
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578631
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578633
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578635
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578637
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578639
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578641
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578643
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578645
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578647
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578649
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578651
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578653
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578655
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578657
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578659
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578661
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578663
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578665
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578667
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578669
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578671
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578673
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578675
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578677
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578679
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578681
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578683
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578685
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578687
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578707
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578709
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578711
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578713
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578715
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578717
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578719
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578721
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578723
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578725
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578727
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578729
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578731
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578733
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578735
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578737
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578739
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578741
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578743
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578745
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578747
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578749
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578751
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578753
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578755
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578757
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578759
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578767
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578769
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578771
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578773
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578775
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578777
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578779
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578781
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578783
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578785
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578787
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578789
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578791
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578793
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578795
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578797
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578799
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578801
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578803
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578805
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578807
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578809
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578811
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578813
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578815
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578817
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578819
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578821
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578823
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578825
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578827
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578829
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578831
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578833
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578837
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578839
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578841
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578843
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578845
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578847
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578849
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578851
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578853
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578855
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578857
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578859
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578861
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578867
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578869
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578871
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578873
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578875
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578877
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578879
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578881
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578883
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578885
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578899
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578901
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578903
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578905
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578907
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578909
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578911
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578913
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578915
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578917
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578919
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578921
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578923
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578925
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578927
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578929
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578931
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578935
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578937
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578939
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578941
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578943
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578945
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578947
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578949
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578951
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578953
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578955
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578957
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578959
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578961
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578963
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578965
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578967
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578969
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578971
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578973
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578975
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578977
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578985
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578987
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578989
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578991
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578993
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578995
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578997
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578999
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579001
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579003
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579005
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579007
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579009
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579011
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579013
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579021
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579023
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579025
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579027
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579029
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579033
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579035
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579037
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579039
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579041
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579043
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579045
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579047
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579049
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579051
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579053
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579055
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579057
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579059
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579061
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579063
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579065
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579067
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579069
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579071
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579073
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579075
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579077
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579079
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579083
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579085
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579087
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579089
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579091
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579093
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579095
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579097
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579099
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579101
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579103
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579105
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579107
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579109
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579111
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579113
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579115
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579117
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579119
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579121
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579123
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579125
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579127
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579129
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579131
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579141
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579143
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579145
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579147
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579149
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579151
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579153
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579155
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579157
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579159
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579161
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579163
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579165
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579167
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579169
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579171
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579173
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579175
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579177
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579179
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579181
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579183
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579185
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579187
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579189
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579191
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579193
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579195
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579197
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579199
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579211
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579213
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579215
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579217
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579219
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579221
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579223
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579225
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579227
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579229
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579231
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579233
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579235
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579237
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579239
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579241
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579243
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579245
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579247
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579249
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579251
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579253
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579255
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579257
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579259
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579261
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579263
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579265
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579267
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579273
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579275
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579277
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579279
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579281
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579283
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579287
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579289
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579291
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579293
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579295
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579297
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579299
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579301
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579303
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579309
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579311
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579313
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579315
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579317
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579319
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579321
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579323
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579325
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579327
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579329
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579331
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579333
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579335
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579337
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579339
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579341
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579343
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579345
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579347
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579349
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579351
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579353
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579355
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579357
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579359
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579369
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579371
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579373
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579375
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579377
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579379
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579381
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579383
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579385
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579387
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579389
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579391
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579393
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579395
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579397
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579399
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579401
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579403
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579405
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579407
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579409
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579411
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579413
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579421
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579423
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579425
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579427
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579429
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579431
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579433
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579435
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579437
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579439
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579441
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579443
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579445
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579447
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579449
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579451
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579453
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579455
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579457
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579459
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579461
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579463
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579477
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579479
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579481
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579483
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579485
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579487
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579489
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579491
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579493
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579495
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579497
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579499
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579501
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579503
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579505
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579507
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579509
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579511
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579513
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579515
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579517
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579519
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579521
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579523
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579525
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579527
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579529
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579531
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579537
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579539
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579541
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579543
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579545
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579547
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579549
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579551
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579553
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579555
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579557
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579559
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579561
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579563
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579571
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579573
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579575
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579577
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579579
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579581
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579583
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579585
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579587
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579589
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579591
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579593
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579595
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579609
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579611
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579613
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579615
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579617
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579619
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579621
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579623
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579625
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579627
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579629
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579631
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579633
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579635
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579637
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579639
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579641
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579643
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579645
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579647
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579649
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579651
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579653
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579655
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579657
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579659
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579661
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579663
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579665
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579667
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579685
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579687
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579689
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579691
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579693
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579695
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579697
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579699
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579701
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579703
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579705
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579707
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579709
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579711
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579713
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579715
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579717
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579719
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579721
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579723
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579725
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579727
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579729
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579731
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579733
Principal investigator 1 ModernaTX, Inc. $812.82 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579735
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579737
Principal investigator 1 ModernaTX, Inc. $13.80 11/21/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579739
Principal investigator 1 PFIZER INC. $167.67 11/19/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759721
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575965
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575967
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575969
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575971
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963575973
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576191
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576193
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576195
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576197
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576199
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576201
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576287
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576289
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576309
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576311
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576389
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576431
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576433
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576435
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576469
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576471
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576525
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576527
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576529
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576587
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576589
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576591
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576621
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576623
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576625
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576627
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576687
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576689
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576767
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576769
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576823
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576825
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576917
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576983
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576985
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577025
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577027
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577029
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577031
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577033
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577035
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577059
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577061
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577063
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577107
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577109
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577111
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577113
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577115
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577131
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577133
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577135
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577137
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577171
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577173
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577175
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577267
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577269
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577271
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577343
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577345
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577347
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577383
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577385
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577437
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577439
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577441
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577463
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577547
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577549
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577551
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577599
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577601
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577603
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577605
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577607
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577609
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577685
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577757
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577759
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577841
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577843
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577845
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577847
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577849
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577851
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577883
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577885
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577887
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577933
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577935
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577937
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577939
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577989
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577991
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578053
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578055
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578057
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578123
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578125
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578205
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578207
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578209
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578211
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578213
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578215
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578239
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578241
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578375
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578439
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578441
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578443
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578445
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578503
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578505
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578507
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578509
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578585
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578587
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578589
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578689
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578691
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578693
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578695
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578697
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578699
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578701
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578703
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578705
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578761
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578763
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578765
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578863
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578865
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578887
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578889
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578891
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578893
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578895
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578897
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578933
Principal investigator 1 ModernaTX, Inc. $2,547.48 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578979
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578981
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578983
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579015
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579017
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579019
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579031
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579081
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579133
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579135
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579137
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579139
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579201
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579203
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579205
Principal investigator 1 ModernaTX, Inc. $1,956.84 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579207
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579209
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579269
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579271
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579285
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579307
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579361
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579363
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579365
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579367
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579415
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579417
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579419
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579465
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579467
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579469
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579471
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579473
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579475
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579533
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579535
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579567
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579569
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579597
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579599
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579601
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579603
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579605
Principal investigator 1 ModernaTX, Inc. $3,655.62 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579607
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579669
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579671
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579673
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579675
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579677
Principal investigator 1 ModernaTX, Inc. $812.82 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579679
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579681
Principal investigator 1 ModernaTX, Inc. $13.80 11/17/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579683
Principal investigator 1 PFIZER INC. $74.52 11/16/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759719
Principal investigator 1 PFIZER INC. $37.26 11/15/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759723
Principal investigator 1 PFIZER INC. $9,500.00 11/10/2022 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780277
Principal investigator 1 ModernaTX, Inc. $166.50 11/09/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963563333
Principal investigator 1 PFIZER INC. $74.52 11/04/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759891
Principal investigator 1 ModernaTX, Inc. $300.00 11/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963563331
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576189
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576523
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963576875
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963577381
Principal investigator 1 ModernaTX, Inc. $2,500.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963578315
Principal investigator 1 ModernaTX, Inc. $2,500.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579305
Principal investigator 1 ModernaTX, Inc. $8,000.00 10/26/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963579565
Principal investigator 1 PFIZER INC. $55.89 10/18/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759887
Principal investigator 1 PFIZER INC. $55.89 10/18/2022 Non-covered Recipient Entity
ClinicalResearchPartnersLLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759889
Principal investigator 1 ModernaTX, Inc. $60.00 10/05/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963563335
Principal investigator 1 ModernaTX, Inc. $167.50 10/04/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963563337
Principal investigator 1 ModernaTX, Inc. $498.00 09/02/2022 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963563319